Protagonist Therapeutics, Inc (PTGX): Shareholders' Equity
$614.71M
As of 2025-12-31
$841.54M
As of 2026-06-30
+41.8%
3-year compound annual growth
+17.1%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $614.71M | -9.0% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $675.29M | +100.6% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $336.68M | +56.2% | 2026-02-25, Balance as of period end |
| 2022-12-31 | $215.61M | -28.1% | 2025-02-21, Balance as of period end |
| 2021-12-31 | $300.02M | +7.3% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $279.61M | +249.7% | 2023-03-15, Balance as of period end |
| 2019-12-31 | $79.96M | -28.9% | 2022-02-28, Balance as of period end |
| 2018-12-31 | $112.52M | -6.7% | 2021-03-10, Balance as of period end |
| 2017-12-31 | $120.63M | +37.8% | 2020-03-10, Balance as of period end |
| 2016-12-31 | $87.56M | n/m | 2019-03-12, Balance as of period end |
| 2015-12-31 | -$27.40M | n/m | 2018-03-07, Balance as of period end |
| 2014-12-31 | -$12.62M | n/a | 2017-03-07, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $614.71M | -9.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $381.93M | -9.1% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | -$33.66M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $24.88M | +8.9% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $17.67M | -13.0% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $35.27M | +100.4% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$122.76M | n/m |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $518.36M | +147.4% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $107.54M | -26.3% |
Compare PTGX, SEPN, AQST, CPIX side by side · Screen every company in Pharmaceutical Preparations ↗